Company Overview
THERAVANCE BIOPHARMA, INC.
TBPHRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
107M
2025 FY
Net Income
106M
2025 FY
Shares Outstanding
50M
2025 FY
EPS
2.1USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1583107
Exchange
Nasdaq
Location
KY